Biomea Fusion (BMEA) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 41.5% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -95.2% for BMEA. Biomea Fusion is the larger company by market cap ($41.7 million vs $41.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | MREO |
|---|---|---|
| Share price | $0.5744 | $0.26 |
| Market cap | $41.75M | $41.52M |
| 1-day change | -2.38% | -5.45% |
| YTD return | -53.68% | -37.65% |
| 1-year return | -41.51% | -85.56% |
| 5-year return | -95.21% | -86.32% |
| EPS (TTM) | $-0.10 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $500.00K |
| Net income (latest FY) | $-61.80M | $-41.88M |
| Operating margin | — | -8021.40% |
| Net margin | — | -8375.60% |
| 52-week high | $2.24 | $2.37 |
| 52-week low | $0.45 | $0.20 |
| Distance from 52-week high | -74.32% | -89.03% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1118.66% | +653.85% |
| Average volume | 2.22M | 1.24M |
| Shares outstanding | 72.68M | 159.70M |
| Employees | 37 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed MREO by 44.0 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
BMEA vs MREO FAQ
Which is bigger, Biomea Fusion or Mereo BioPharma Group?
Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $41.52M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, BMEA or MREO?
BMEA returned -41.51% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.